Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
Articles
FDA Accelerates Approval of Akeega, the First Dual-Action Tablet for BRCA-Mutated Metastatic Prostate Cancer
FDA Approvals, News & Updates
,
Prostate Cancer
October 2023, Vol 14, No 5
On
August 11, 2023
, the FDA accelerated the approval of the fixed-dose combination of niraparib and abiraterone acetate (Akeega; Janssen Biotech), with prednisone, for the treatment of adults with deleterious or suspected deleterious
BRCA
-mutated, castration-resistant prostate cancer, as determined by an FDA-approved test. The FDA granted this approval priority review.
Read More
Gavreto Receives Regular Approval for Patients With RET-Positive NSCLC
FDA Approvals, News & Updates
,
Lung Cancer
October 2023, Vol 14, No 5
On
August 9, 2023
, the FDA granted regular approval to pralsetinib (Gavreto; Genentech), a kinase inhibitor of wild-type
RET
and oncogenic
RET
fusions and mutations, for the treatment of adults with metastatic non–small cell lung cancer (NSCLC) and
RET
fusion–positive gene mutation, as detected by an FDA-approved test.
Read More
Zanidatamab Demonstrates Efficacy in Refractory HER2-Amplified Biliary Tract Cancer
Emerging Therapies
,
ASCO 2023 Highlights
October 2023, Vol 14, No 5
Improving clinical outcomes in the second line of treatment in patients with advanced biliary tract cancer remains an important goal, and researchers have been exploring various therapeutic targets, including
HER2
, an oncogene that creates a protein that encourages cell growth and accelerates the spread of cancers.
Read More
Loss of Y Chromosome in Men Makes Bladder Cancer More Aggressive
By
Nadia Jaber
Personalized Medicine
,
Bladder Cancer
,
Genitourinary Cancers
October 2023, Vol 14, No 5
It was once thought that after guiding the development of male sex organs in a fetus, the Y chromosome did not do much else. But over the past few years, results from multiple studies have challenged that belief.
Read More
AMA Examines Decade of Change in Physician Practice Ownership and Organization
Healthcare Administration
October 2023, Vol 14, No 5
Chicago, IL—Physicians are less likely to work in a private practice than 10 years ago due to economic, administrative, and regulatory burdens that have driven physicians to shift traditional business models for medical practices, according to a newly released biennial analysis of physician practice arrangements by the American Medical Association.
Read More
Updated ASCO Guidelines Reiterate the Importance of Geriatric Assessment in Older Patients With Cancer
Oncology Practice
,
ASCO 2023 Highlights
,
Geriatric Cancer
October 2023, Vol 14, No 5
The American Society of Clinical Oncology has issued an update to its guidelines for the practical assessment and management of vulnerabilities in patients aged ≥65 years receiving systemic cancer treatment.
Read More
Study Shows How Morphine May Contribute to Bone Loss and Cancer-Induced Bone Pain
Symptom Management
Online First
Opioids such as morphine are the gold standard for treating cancer-induced bone pain, but new University of Arizona Health Sciences research recently published in
PAIN
uncovered a mechanism by which chronic morphine use may increase bone loss and pain.
Read More
Why Your Claims Are Getting Denied—and What to Do About It
By
Juan Arredondo
;
Bri Driggers
Reimbursement
Online First
Medicine is an essential service. Yet, healthcare providers still need to make enough profit to cover their overhead costs if they want to keep their doors open. That is why it is essential for your business and community that claims are processed accurately and that you get reimbursed for your services.
Read More
Bringing Stakeholders Together Bringing Stakeholders Together
AVBCC
Videos
For executives like Andrew Hertler, MD, FACP, CMO, New Century Health, the annual AVBCC Educational Summit & Program is the single best conference for meeting with a large number of peers simultaneously.
Read More
Improving Diversity in Clinical Trials
By
Phoebe Starr
Disparities in Cancer Care
,
ASCO 2023 Highlights
August 2023, Vol 14, No 4
Chicago, IL—It is well documented that clinical trials thus far have for the most part excluded underserved populations, and that means the results of these trials cannot be generalized to society at large. Fortunately, the federal government and medical societies have taken aim at remedying this imbalance in accrual for clinical trials.
Read More
Page 4 of 338
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma